Wolters Kluwer Update on Share Buyback Program

ALPHEN AAN DEN RIJN, Netherlands, June 18, 2015 (GLOBE NEWSWIRE) -- Wolters Kluwer announces that, so far this year, it has repurchased 3.9 million ordinary shares for a total consideration of €111 million. These repurchases have been made as part of the up to €140 million share buyback program announced in February 2015.

The repurchased shares are added to and held as treasury shares, which total 9.1 million as of today. In accordance with regulatory requirements to report a holding when it equals or exceeds 3%, the company has notified the Dutch Authority Financial Markets.

About Wolters Kluwer Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information about our products and organization, visit www.wolterskluwer.com, follow @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.

PDF version of Press Release http://hugin.info/130682/R/1929509/693162.pdf

HUG#1929509

You May Also Be Interested In

• Gina Reyes Mortgage Broker Announces Expanded Multi State Mortgage Services Backed by Two Decades of Underwriting Experience
• LOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use
• Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma